CTOs on the Move


 
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ambrx.com
  • 10975 North Torrey Pines Road
    La Jolla, CA USA 92037
  • Phone: 858.875.2400

Executives

Name Title Contact Details

Funding

Ambrx raised $45M on 08/05/2016
Ambrx raised $200M on 11/09/2020

Similar Companies

Bellus Health

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

Brain Cells

Brain Cells is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Premiera Care Communities

Premiera Care Communities is a Oakdale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Network Biosystems

Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoImmune

Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.